DexCom Sets High Bar in Growing CGM Space

article image

DexCom is a dominant force in the continuous glucose monitoring (CGM) market, but the company is not about to rest on its laurels. The MedTech Strategist recently spoke at length with DexCom CEO Kevin Sayer about the challenges of breaking down longstanding barriers to CGM access and adoption, and what the future might bring for this industry.

Founded in 1999, diabetes device pure-play DexCom Inc. has grown into a powerhouse in the continuous glucose monitoring (CGM) arena.

This article is restricted to subscribers only.

To continue reading, select one of the options below:

Existing Subscriber?

Sign In to continue reading.

Need Multi-User Access?

Gain access for your entire organization.

Get Quote Check to see if your company already has access

Subscribe to MedTech Strategist:

Actionable intelligence exploring the people, challenges, and opportunities impacting the global medtech community.

Subscribe to MedTech Strategist
Subscribe to ELITE Strategist

Become an ELITE Strategist and unlock access to both MedTech Strategist and MTS Market Pathways.

Subscribe to Elite


We're here to help! Please contact us at: